440 related articles for article (PubMed ID: 29392687)
1. Whole Genome Sequencing-Based Discovery of Structural Variants in Glioblastoma.
Wrzeszczynski KO; Felice V; Shah M; Rahman S; Emde AK; Jobanputra V; O Frank M; Darnell RB
Methods Mol Biol; 2018; 1741():1-29. PubMed ID: 29392687
[TBL] [Abstract][Full Text] [Related]
2. Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development.
Koga T; Li B; Figueroa JM; Ren B; Chen CC; Carter BS; Furnari FB
Neuro Oncol; 2018 Sep; 20(10):1310-1320. PubMed ID: 29660021
[TBL] [Abstract][Full Text] [Related]
3. From cytogenetics to cytogenomics: whole-genome sequencing as a first-line test comprehensively captures the diverse spectrum of disease-causing genetic variation underlying intellectual disability.
Lindstrand A; Eisfeldt J; Pettersson M; Carvalho CMB; Kvarnung M; Grigelioniene G; Anderlid BM; Bjerin O; Gustavsson P; Hammarsjö A; Georgii-Hemming P; Iwarsson E; Johansson-Soller M; Lagerstedt-Robinson K; Lieden A; Magnusson M; Martin M; Malmgren H; Nordenskjöld M; Norling A; Sahlin E; Stranneheim H; Tham E; Wincent J; Ygberg S; Wedell A; Wirta V; Nordgren A; Lundin J; Nilsson D
Genome Med; 2019 Nov; 11(1):68. PubMed ID: 31694722
[TBL] [Abstract][Full Text] [Related]
4. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
[TBL] [Abstract][Full Text] [Related]
5. Clinical-grade validation of whole genome sequencing reveals robust detection of low-frequency variants and copy number alterations in CLL.
Klintman J; Barmpouti K; Knight SJL; Robbe P; Dreau H; Clifford R; Ridout K; Burns A; Timbs A; Bruce D; Antoniou P; Sosinsky A; Becq J; Bentley D; Hillmen P; Taylor JC; Caulfield M; Schuh AH
Br J Haematol; 2018 Aug; 182(3):412-417. PubMed ID: 29808933
[TBL] [Abstract][Full Text] [Related]
6. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants.
Belkadi A; Bolze A; Itan Y; Cobat A; Vincent QB; Antipenko A; Shang L; Boisson B; Casanova JL; Abel L
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5473-8. PubMed ID: 25827230
[TBL] [Abstract][Full Text] [Related]
7. Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer.
Wrzeszczynski KO; Felice V; Abhyankar A; Kozon L; Geiger H; Manaa D; London F; Robinson D; Fang X; Lin D; Lamendola-Essel MF; Khaira D; Dikoglu E; Emde AK; Robine N; Shah M; Arora K; Basturk O; Bhanot U; Kentsis A; Mansukhani MM; Bhagat G; Jobanputra V
J Mol Diagn; 2018 Nov; 20(6):822-835. PubMed ID: 30138725
[TBL] [Abstract][Full Text] [Related]
8. A survey of tools for variant analysis of next-generation genome sequencing data.
Pabinger S; Dander A; Fischer M; Snajder R; Sperk M; Efremova M; Krabichler B; Speicher MR; Zschocke J; Trajanoski Z
Brief Bioinform; 2014 Mar; 15(2):256-78. PubMed ID: 23341494
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the performance of copy number variant prediction tools for the detection of deletions from whole genome sequencing data.
Whitford W; Lehnert K; Snell RG; Jacobsen JC
J Biomed Inform; 2019 Jun; 94():103174. PubMed ID: 30965134
[TBL] [Abstract][Full Text] [Related]
10. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.
Francis JM; Zhang CZ; Maire CL; Jung J; Manzo VE; Adalsteinsson VA; Homer H; Haidar S; Blumenstiel B; Pedamallu CS; Ligon AH; Love JC; Meyerson M; Ligon KL
Cancer Discov; 2014 Aug; 4(8):956-71. PubMed ID: 24893890
[TBL] [Abstract][Full Text] [Related]
11. Discovering gene-environment interactions in glioblastoma through a comprehensive data integration bioinformatics method.
Kunkle B; Yoo C; Roy D
Neurotoxicology; 2013 Mar; 35():1-14. PubMed ID: 23261424
[TBL] [Abstract][Full Text] [Related]
12. Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.
Pestinger V; Smith M; Sillo T; Findlay JM; Laes JF; Martin G; Middleton G; Taniere P; Beggs AD
Mol Diagn Ther; 2020 Jun; 24(3):339-349. PubMed ID: 32306292
[TBL] [Abstract][Full Text] [Related]
13. NGS for Sequence Variants.
Teng S
Adv Exp Med Biol; 2016; 939():1-20. PubMed ID: 27807741
[TBL] [Abstract][Full Text] [Related]
14. Practical Bioinformatic DNA-Sequencing Pipeline for Detecting Oncogene Amplification and EGFRvIII Mutational Status in Clinical Glioblastoma Samples.
Miller ML; Tome-Garcia J; Waluszko A; Sidorenko T; Kumar C; Ye F; Tsankova NM
J Mol Diagn; 2019 May; 21(3):514-524. PubMed ID: 31000415
[TBL] [Abstract][Full Text] [Related]
15. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.
Rosenberg S; Verreault M; Schmitt C; Guegan J; Guehennec J; Levasseur C; Marie Y; Bielle F; Mokhtari K; Hoang-Xuan K; Ligon K; Sanson M; Delattre JY; Idbaih A
Neuro Oncol; 2017 Feb; 19(2):219-228. PubMed ID: 27571888
[TBL] [Abstract][Full Text] [Related]
16. Improved molecular karyotyping in glioblastoma.
Burbulis IE; Wierman MB; Wolpert M; Haakenson M; Lopes MB; Schiff D; Hicks J; Loe J; Ratan A; McConnell MJ
Mutat Res; 2018 Sep; 811():16-26. PubMed ID: 30055482
[TBL] [Abstract][Full Text] [Related]
17. Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers.
Li X; Kumar S; Harmanci A; Li S; Kitchen RR; Zhang Y; Wali VB; Reddy SM; Woodward WA; Reuben JM; Rozowsky J; Hatzis C; Ueno NT; Krishnamurthy S; Pusztai L; Gerstein M
Genome Med; 2021 Apr; 13(1):70. PubMed ID: 33902690
[TBL] [Abstract][Full Text] [Related]
18. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.
Hintzsche J; Kim J; Yadav V; Amato C; Robinson SE; Seelenfreund E; Shellman Y; Wisell J; Applegate A; McCarter M; Box N; Tentler J; De S; Robinson WA; Tan AC
J Am Med Inform Assoc; 2016 Jul; 23(4):721-30. PubMed ID: 27026619
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Whole Genome Sequencing Data.
Hübschmann D; Schlesner M
Methods Mol Biol; 2019; 1956():321-336. PubMed ID: 30779042
[TBL] [Abstract][Full Text] [Related]
20. Whole genome sequencing of matched tumor, adjacent non-tumor tissues and corresponding normal blood samples of hepatocellular carcinoma patients revealed dynamic changes of the mutations profiles during hepatocarcinogenesis.
Mao R; Liu J; Liu G; Jin S; Xue Q; Ma L; Fu Y; Zhao N; Xing J; Li L; Qiu Y; Lin B
Oncotarget; 2017 Apr; 8(16):26185-26199. PubMed ID: 28412734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
